Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

The Strides-backed protein and peptide-based therapeutics developer has disclosed a $70m series B and $125m C round, valuing it at $350m post-money.

Novartis and Bristol Myers Squibb helped the alpha radiotherapy developer complete a series A round after being incubated by MPM Capital.

Madryn Asset Management has provided debt and equity financing intended to help Abbott-backed Bigfoot Biomedical bring its diabetes management technology to market.

VIB’s antiviral treatment developer has closed its series A round following a $22.6m extension backed by the research institute, V-Bio Ventures and Vives Inter-University Fund.

UCB’s corporate venture capital unit has helped the antiviral treatment developer close its series A round, joining a $22.6m extension.

Salesforce Ventures and Optum Ventures helped the healthcare network technology provider push its valuation above $1.6bn and its total funding to near $200m.

Insight Partners and Scale Venture Partners co-led a series C round for the GV-backed stroke detection software provider, taking its total funding to $150m.

Eli Lilly and Novartis Venture Fund participated in a round that will support the progress of Amphista's protein degradation drug candidates toward clinical trials.

Forbion and Gilde Healthcare have co-led a $53m series B round for Dundee spinout Amphista, which is working on targeted protein degradation technology.